The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
News|Articles|January 2, 2005
- Pharmaceutical Technology-01-02-2005
- Volume 29
- Issue 1
The Pipeline Crisis
Committees make prudent decisions and avoid mistakes, but they're afraid of the new.
Advertisement
Articles in this issue
almost 22 years ago
An Overview of the Effect of Moisture on Compaction and Compressionalmost 22 years ago
The Outsourcing Advantages in Formulation Developmentalmost 22 years ago
Drug Safety and Access Top Policy Concerns for 2005almost 22 years ago
Comparison of EP "Heavy Metals" Test with USP "Conductivity" Testalmost 22 years ago
Patheon Places Big Bet with Mova Acquisitionalmost 22 years ago
January 2005almost 22 years ago
In the Spotlight-January 2005Advertisement
Related to this article
France’s 2030 Health Initiative is driving growth in biotechnology, health innovation, biomanufacturing, and digital health.
argenx will acquire Unnatural Products for up to $1.15B, bringing oral macrocyclic peptides and new formulation challenges to its antibody portfolio.
Boehringer, AbbVie, ASKA, and Evommune license ADC, IBD, thyroid eye disease, and degrader assets, raising tech transfer demands for manufacturers.
Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5